RadSite has enhanced its quality-based mission by recently expanding its on-site audit program. In addition to the assessment criteria that are filled out by imaging providers as part of the application process, RadSite has ramped up its auditing to ensure compliance with RadSite Standards.
The enhanced on-site audit program is designed to assess how imaging personnel are implementing their quality practices and maintaining their imaging equipment. The audits also are designed to be an educational process that promotes best practices. RadSite also carries out desktop audits to validate its review of imaging practices.
RadSite audits ensure the policies cited on the RadSite assessment are carried out in day-to-day clinical practice. Auditors review the equipment, overall aspects of the site, and documentation requested in a pre-audit email. “The on-site audit process insures that facilities are meeting a high quality of patient care and allows the facilities to receive expert guidance in such areas as radiation safety, quality clinical practice, and imaging protocols,” says Phillip W. Patton, PhD CHP DABR, RadSite’s on-site audit coordinator and staff physicist.
In addition to the random on-site audits, RadSite also will audit imaging providers if they are deemed out of compliance with the RadSite Assessment or Accreditation Program Standards.
“RadSite offers a process that is both collaborative and educational; we encourage facilities to take advantage of the expertise these professionals bring and ask questions,” says Garry Carneal, RadSite president & CEO. “With imaging becoming a more integral part of medical care—and the increased costs of advanced diagnostic and therapeutic interventions—RadSite is dedicated to ensuring that imaging systems are functioning properly to best meet the safety and medical needs of patients.”
“Providers who are quality-certified are listed on RadSite’s website. The desktop and on-site audit process serves to ensure the integrity of the certification process,” says Junellen Neese, RadSite’s director of program development. Most recently, RadSite has audited facilities across the country, including Florida, Georgia, Kentucky, Nevada, California, and South Carolina. On an annualized basis, RadSite visits hundreds of different imaging providers as part of its on-site audit review program.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.